 |
138 Diseases |  |
94 Trials |
|
94 Trials |  |
2090 News |  |
| «12...21222324252627282930313233» |
- leuprolide acetate for depot suspension / Generic mfg., anastrozole / Generic mfg.
Enrollment change, Trial withdrawal: Study of the Effect of Testosterone and Estradiol on NP Responses to Acute and Chronic Salt Loading (clinicaltrials.gov) - Nov 13, 2014
P0, N=0, Withdrawn, Sponsor: Massachusetts General Hospital
N=250 --> 0 | Not yet recruiting --> Withdrawn
- leuprolide acetate for depot suspension / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Study of a Progestin to Prevent Bleeding Associated With Initiation of Medical Menopause With GnRH Agonist (clinicaltrials.gov) - Nov 11, 2014
P4, N=8, Terminated, Sponsor: Malcolm G. Munro
N=250 --> 0 | Not yet recruiting --> Withdrawn N=40 --> 8 | Recruiting --> Terminated | Trial primary completion date: Jan 2013 --> Apr 2014; Inadequate enrollment
- | docetaxel / Generic mfg.
Enrollment closed: Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer (clinicaltrials.gov) - Nov 6, 2014
P1/2, N=25, Active, not recruiting, Sponsor: University of Kansas
N=40 --> 8 | Recruiting --> Terminated | Trial primary completion date: Jan 2013 --> Apr 2014; Inadequate enrollment Recruiting --> Active, not recruiting
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
New P2 trial: Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer (clinicaltrials.gov) - Oct 30, 2014
P2, N=56, Not yet recruiting, Sponsor: University of Colorado, Denver
- |||| anastrozole/levonorgestrel (BAY 98-7196) / Bayer
Enrollment open: Bay98-7196, Dose Finding / POC Study (clinicaltrials.gov) - Oct 24, 2014
P2b, N=324, Recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- leuprolide acetate for depot suspension / Generic mfg.
Trial primary completion date: Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation (clinicaltrials.gov) - Oct 20, 2014
P2, N=236, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2016 --> Apr 2017
- ||||||| leuprolide acetate for depot suspension / Generic mfg.
Trial completion: A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy (clinicaltrials.gov) - Oct 17, 2014
P3, N=160, Completed, Sponsor: Takeda
Trial primary completion date: Apr 2016 --> Apr 2017 Recruiting --> Completed
- docetaxel / Generic mfg.
Trial primary completion date: Neoadjuvant Hormones + Docetaxel in Node-Positive Prostate Cancer (clinicaltrials.gov) - Oct 15, 2014
P2, N=40, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Completed Trial primary completion date: May 2015 --> May 2016
- || progesterone / Generic mfg.
New P3 trial: GnRH Agonist and Progesterone Versus Progesterone Only for Luteal Phase Support in Antagonist Cycles (clinicaltrials.gov) - Oct 15, 2014
P3, N=200, Not yet recruiting, Sponsor: Queensland Fertility Group
- ||||| orteronel (TAK 700) / Takeda
Enrollment closed: Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer (clinicaltrials.gov) - Oct 10, 2014
P3, N=900, Active, not recruiting, Sponsor: Radiation Therapy Oncology Group
Trial primary completion date: May 2015 --> May 2016 Recruiting --> Active, not recruiting
- ||||| leuprolide acetate for depot suspension / Generic mfg.
Enrollment change, Trial initiation date, Trial primary completion date: A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer (clinicaltrials.gov) - Oct 4, 2014
P3, N=120, Recruiting, Sponsor: Takeda
Recruiting --> Active, not recruiting N=240 --> 120 | Initiation date: Mar 2013 --> Jun 2013 | Trial primary completion date: Sep 2015 --> Apr 2016
- leuprolide acetate for depot suspension / Generic mfg.
Enrollment change: Down-regulated Hormonally Controlled Cycles for Vitrification-warmed Blastocyst Transfers (clinicaltrials.gov) - Sep 19, 2014
P=N/A, N=300, Not yet recruiting, Sponsor: Antalya IVF
N=240 --> 120 | Initiation date: Mar 2013 --> Jun 2013 | Trial primary completion date: Sep 2015 --> Apr 2016 N=200 --> 300
- || Sutent (sunitinib) / Pfizer
Trial primary completion date: Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy (clinicaltrials.gov) - Sep 11, 2014
P2, N=64, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
N=200 --> 300 Trial primary completion date: Dec 2014 --> Dec 2015
- zoledronic acid / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion, Trial primary completion date, Metastases: Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases (clinicaltrials.gov) - Sep 11, 2014
P2, N=80, Completed, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Dec 2014 --> Dec 2015 Active, not recruiting --> Completed | Trial primary completion date: May 2016 --> Sep 2014
- docetaxel / Generic mfg.
Trial primary completion date: Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer (clinicaltrials.gov) - Sep 4, 2014
P1/2, N=25, Recruiting, Sponsor: University of Kansas
Active, not recruiting --> Completed | Trial primary completion date: May 2016 --> Sep 2014 Trial primary completion date: Mar 2014 --> Mar 2015
- opigolix (ASP1707) / Astellas
Enrollment closed: A Study to Assess the Effectiveness and Safety of Different Doses of ASP1707 Compared to Placebo for Endometriosis Associated Pelvic Pain (clinicaltrials.gov) - Aug 21, 2014
P2, N=600, Active, not recruiting, Sponsor: Astellas Pharma Europe B.V.
Trial primary completion date: Mar 2014 --> Mar 2015 Recruiting --> Active, not recruiting
- Xtandi (enzalutamide capsule) / Pfizer, Astellas
Enrollment open, Metastases: LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer (clinicaltrials.gov) - Aug 12, 2014
P2, N=92, Recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Trial termination, Surgery, Biopsy: Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA (clinicaltrials.gov) - Aug 5, 2014
P2, N=2, Terminated, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Not yet recruiting --> Recruiting Completed --> Terminated; low accrual
- |||| Trial completion: The Clinical Trial to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide Acetate 3.75mg) in Patients With Precocious Puberty (clinicaltrials.gov) - Aug 4, 2014
P4, N=63, Completed, Sponsor: Daewoong Pharmaceutical Co. LTD.
Completed --> Terminated; low accrual Active, not recruiting --> Completed
- |||||| anastrozole/levonorgestrel (BAY 98-7196) / Bayer
New P2b trial: Bay98-7196, Dose Finding / POC Study (clinicaltrials.gov) - Jul 30, 2014
P2b, N=324, Not yet recruiting, Sponsor: Bayer
- Ibrance (palbociclib) / Pfizer
Enrollment open, Trial initiation date, Metastases: A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer (clinicaltrials.gov) - Jul 17, 2014
P2, N=60, Recruiting, Sponsor: University of Michigan Cancer Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Feb 2014 --> Jun 2014
- leuprolide acetate for depot suspension / Generic mfg.
Trial termination: Post-operative or Early Salvage XRT and ADT for High Risk PCa (clinicaltrials.gov) - Jul 8, 2014
P3, N=87, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Not yet recruiting --> Recruiting | Initiation date: Feb 2014 --> Jun 2014 Recruiting --> Terminated; Poorly recruiting
- leuprolide acetate for depot suspension / Generic mfg.
Trial initiation date: Post-operative or Early Salvage XRT and ADT for High Risk PCa (clinicaltrials.gov) - Jul 8, 2014
P3, N=87, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Recruiting --> Terminated; Poorly recruiting Initiation date: May 2009 --> Oct 2009
- leuprolide acetate for depot suspension / Generic mfg.
Enrollment change, Trial initiation date, Trial termination: Post-operative or Early Salvage XRT and ADT for High Risk PCa (clinicaltrials.gov) - Jul 8, 2014
P3, N=87, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Initiation date: May 2009 --> Oct 2009 N=600 --> 87 | Initiation date: May 2009 --> Oct 2009 | Recruiting --> Terminated; Poorly recruiting
- Yervoy (ipilimumab) / Ono Pharma, BMS
Trial primary completion date, IO biomarker: Neoadjuvant Ipilimumab in Prostate Cancer (clinicaltrials.gov) - Jul 2, 2014
P2a, N=20, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
N=600 --> 87 | Initiation date: May 2009 --> Oct 2009 | Recruiting --> Terminated; Poorly recruiting Trial primary completion date: Sep 2014 --> Sep 2015
- zoledronic acid / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial primary completion date, Metastases: Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases (clinicaltrials.gov) - Jul 2, 2014
P2, N=80, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Sep 2014 --> Sep 2015 Trial primary completion date: May 2014 --> May 2016
- ||| Kepivance (palifermin) / SOBI, Amgen, Firmagon (degarelix) / Astellas, Ferring
Enrollment change: Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Jul 2, 2014
P2, N=120, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Trial primary completion date: May 2014 --> May 2016 N=180 --> 120
- ||| leuprorelin depot / Generic mfg.
Clinical: Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey "Long-term Use Survey in Prostate Cancer Patients (96 Weeks)" (clinicaltrials.gov) - Jun 19, 2014
P=N/A, N=11288, Completed, Sponsor: Takeda
- |||| Trial primary completion date: Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence (clinicaltrials.gov) - Jun 18, 2014
P3, N=496, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
N=180 --> 120 Trial primary completion date: Jun 2015 --> Jun 2016
- leuprolide acetate for depot suspension / Generic mfg.
Phase classification: Influence of Male Hormones on Regional Fat Metabolism (clinicaltrials.gov) - Jun 12, 2014
P1, N=39, Completed, Sponsor: Mayo Clinic
Trial primary completion date: Jun 2015 --> Jun 2016 Phase classification: P=N/A --> P1
- ||| leuprolide acetate for depot suspension / Generic mfg.
Trial completion, Metastases: Observational Program to Assess Use of Intermittent Adjuvant Deprivation Therapy With Leuprorelin (Lucrin Depot) in Patients With Advanced Prostate Cancer (PCa) in Russia (clinicaltrials.gov) - Jun 5, 2014
P=N/A, N=300, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Phase classification: P=N/A --> P1 Active, not recruiting --> Completed
- Trial primary completion date: Effect of GnRH Antagonist vs Agonist Long on IVF Outcome, Peak Estradiol Level,and Duration of Stimulation (clinicaltrials.gov) - Jun 2, 2014
P=N/A, N=43, Completed, Sponsor: Main Line Fertility Center
Active, not recruiting --> Completed Trial primary completion date: Apr 2013 --> May 2014
- | Trial completion: Effect of GnRH Antagonist vs Agonist Long on IVF Outcome, Peak Estradiol Level,and Duration of Stimulation (clinicaltrials.gov) - Jun 2, 2014
P=N/A, N=43, Completed, Sponsor: Main Line Fertility Center
Trial primary completion date: Apr 2013 --> May 2014 Recruiting --> Completed
- ||| leuprorelin depot / Generic mfg.
Clinical: Leuprorelin Acetate SR 11.25 mg for Injection Specified Drug-use Survey "Long-term Use Survey on Premenopausal Breast Cancer Patients (96 Weeks)" (clinicaltrials.gov) - Jun 1, 2014
P=N/A, N=651, Completed, Sponsor: Takeda
- leuprolide acetate for depot suspension / Generic mfg.
New P4 trial: SIU-LNG: Levonorgestrel-releasing Intrauterine System in Patients With Endometriosis (clinicaltrials.gov) - May 30, 2014
P4, N=44, Completed, Sponsor: University of Sao Paulo
- Trial primary completion date, Surgery, Biopsy: Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA (clinicaltrials.gov) - May 15, 2014
P2, N=2, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Recruiting --> Completed Trial primary completion date: May 2013 --> Sep 2013
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
Trial initiation date: Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer (clinicaltrials.gov) - May 12, 2014
P2, N=15, Recruiting, Sponsor: University of Texas Southwestern Medical Center
Trial primary completion date: May 2013 --> Sep 2013 Initiation date: Apr 2014 --> May 2014
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
Enrollment open: Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer (clinicaltrials.gov) - May 12, 2014
P2, N=15, Recruiting, Sponsor: University of Texas Southwestern Medical Center
Initiation date: Apr 2014 --> May 2014 Not yet recruiting --> Recruiting
- ||| leuprorelin depot / Generic mfg.
Clinical: Leuprorelin Acetate SR 11.25 mg Injection Kit Specified Drug-use Survey: "QOL Survey in Premenopausal Breast Cancer Patients" (clinicaltrials.gov) - May 7, 2014
P=N/A, N=2816, Active, not recruiting, Sponsor: Takeda
- |||| Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Trial completion: A Long-term Extension Study of TAK-385 in the Treatment of Endometriosis (clinicaltrials.gov) - May 6, 2014
P2, N=397, Completed, Sponsor: Takeda
Not yet recruiting --> Recruiting Recruiting --> Completed
- | triptorelin / Generic mfg.
Enrollment change, Metastases: GREAT: GP Extended Action Triptorelin (clinicaltrials.gov) - Apr 28, 2014
P4, N=21, Completed, Sponsor: Ipsen
Recruiting --> Completed N=17 --> 21
- | triptorelin / Generic mfg.
Trial completion, Metastases: GREAT: GP Extended Action Triptorelin (clinicaltrials.gov) - Apr 28, 2014
P4, N=21, Completed, Sponsor: Ipsen
N=17 --> 21 Active, not recruiting --> Completed
- Climara (estradiol) / Bausch Health, Bayer
Clinical: Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women (clinicaltrials.gov) - Apr 22, 2014
P=N/A, N=34, Not yet recruiting, Sponsor: University of Colorado, Denver
- Xtandi (enzalutamide capsule) / Pfizer, Astellas
Trial initiation date, Combination therapy: Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer (clinicaltrials.gov) - Apr 21, 2014
P1, N=24, Recruiting, Sponsor: Thomas Jefferson University
Active, not recruiting --> Completed Initiation date: Jun 2014 --> Apr 2014
- Xtandi (enzalutamide capsule) / Pfizer, Astellas
Enrollment open, Combination therapy: Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer (clinicaltrials.gov) - Apr 21, 2014
P1, N=24, Recruiting, Sponsor: Thomas Jefferson University
Initiation date: Jun 2014 --> Apr 2014 Not yet recruiting --> Recruiting
- ||| Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Trial initiation date: A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer (clinicaltrials.gov) - Apr 20, 2014
P2, N=125, Recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
Not yet recruiting --> Recruiting Initiation date: Mar 2014 --> Apr 2014
- |||| Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Enrollment open: A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer (clinicaltrials.gov) - Apr 20, 2014
P2, N=125, Recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
Initiation date: Mar 2014 --> Apr 2014 Not yet recruiting --> Recruiting
- Xtandi (enzalutamide capsule) / Pfizer, Astellas
Enrollment open: Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM) (clinicaltrials.gov) - Apr 15, 2014
P2, N=38, Recruiting, Sponsor: Duke University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- progesterone / Generic mfg., leuprorelin depot / Generic mfg., estradiol valerate / Generic mfg.
Clinical: The Effect of GnRH Agonist Administered in the Luteal Phase on ART Cycle Outcomes (clinicaltrials.gov) - Apr 13, 2014
P=N/A, N=100, Not yet recruiting, Sponsor: Zekai Tahir Burak Maternity and Teaching Hospital
- | stapuldencel-T (DCVAC/PCa) / Sotio
New P2 trial, Combination therapy, Metastases: ASN-002-IL: Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer (clinicaltrials.gov) - Apr 6, 2014
P2, N=63, Active, not recruiting, Sponsor: Sotio a.s.